BioMarin Pharmaceutical (MEX:BMRN) Inventories, Finished Goods: MXN2,178 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
80 GF Score
Price MXN959.00
GF Value MXN1,507.35
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Inventories, Finished Goods?

BioMarin Pharmaceutical MEX:BMRN 80 Inventories, Finished Goods is MXN2,178 Mil as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,507.35 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMarin Pharmaceutical's quarterly finished goods declined from Sep. 2025 (MXN8,910 Mil) to Dec. 2025 (MXN7,046 Mil) and declined from Dec. 2025 (MXN7,046 Mil) to Mar. 2026 (MXN2,178 Mil).

BioMarin Pharmaceutical's annual finished goods increased from Dec. 2023 (MXN6,457 Mil) to Dec. 2024 (MXN11,004 Mil) but then declined from Dec. 2024 (MXN11,004 Mil) to Dec. 2025 (MXN7,046 Mil).

BioMarin Pharmaceutical Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Inventories, Finished Goods Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,767.29 6,869.53 6,456.53 11,004.18 7,045.85

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,602.32 9,054.85 8,909.80 7,045.85 2,177.59
MEX:BMRN
80GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN2,178 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Inventories, Finished Goods of MXN2,178 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Inventories, Finished Goods too high?
BioMarin Pharmaceutical's current Inventories, Finished Goods is MXN2,178 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Inventories, Finished Goods compare to CYTK and ARWR?
BioMarin Pharmaceutical's Inventories, Finished Goods of MXN2,178 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Inventories, Finished Goods is MXN2,178 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,507.35, compared to a current price of MXN959.00 — trading 36.4% below its estimated fair value. The current Inventories, Finished Goods is MXN2,178 Mil. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Inventories, Finished Goods is MXN2,178 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 36.4% below its estimated GF Value™ of MXN1,507.35. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Inventories, Finished Goods: MXN2,178 Mil
  • GF Value™: MXN1,507.35 vs. price of MXN959.00 (36.4% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for MEX:BMRN

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,507.35
GF Value